欢迎来到天天文库
浏览记录
ID:51609201
大小:69.00 KB
页数:3页
时间:2020-03-14
《羟喜树碱联合维拉帕米玻璃体内注射的临床应用研究.doc》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、拜喜树碱联合维拉帕米玻璃体内注射的临床应用研究【关键词】疑喜树碱【摘要】目的应用一定剂量的拜喜树碱(HCPT),维拉帕米(Ver)在玻璃体切割术中注入玻璃体腔内,观察対玻璃体增殖物的抑制作用。方法对51只眼视网膜脱离体伴增生性玻璃体视网膜病变PVR的患者施行•玻璃体手术加玻璃体腔内药物注射,与单纯手术组37只眼视网膜脱离伴PVR做对比观察。结果手术加注药组与单纯手术组比较,术后3〜5个月随访治愈率分别为88.23%,70.27%,两组比较差异有显著性(Pv0.05)。视网膜表而增生膜和网膜下机化膜比术前
2、加重的发牛率分别为13.72%,34.43%,两组比较差异有显著性(PV0.05),手术加注跖组无严重的并发症。结论提示疑喜树碱联合维拉帕米玻璃体腔内注射将是防治PVR的一•种很有效的方法。关键词拜喜树碱(HCPT)维拉帕米(Ver)玻璃体腔内注射增生性玻璃体视网膜病变vPstyle—TEXT-INDENT:24pxualign=center>Intravitrealinjectionofhydroxycamptothecinandverapamil3、lign=center>intreatmentofproliferativevitreoretinopathyRongAo,BiYanlong,LiWen,etal.DepartmentofOphthalmology,TongjiHospitalofTongjiUniversity,Shanghai200065・【Abstract]Objective4、Toinvestigatetheinhibitoryeffectofintravitrealinjectionofhydroxycamptothecin(HCPT)andverapamil(Ver)onproliferativevitreoretinopathy.MethodsFifty-oneeyeswithretinaldetachmentcomplicatedwithproliferativevitreoretinopathyunderwentsurgeryandintravitrealinjec5、tionofhydroxycamptothecin(HCPT)andverapami11(Ver)andfollow-upfor3〜5m()nths.Thecurativeeffectwascomparedwiththatofpurelysurgeryon37eyeswithretina]detachmentcomplicatedwithPVR.ResultsRetinalreattachmentwasfoundinmosteyesinbothgroupspostoperatively.Thecurer6、atewas88.23%inthesurgeryplusinjectiongroupandwas70.2%inpurelysurgerygrouprespectively(P<0.05)・Theworseningrateofepiretinalmembraneandsubretinalmembranewasl3.72%inthesurgeryplusinjectiongroupand32.43%inthepurelysurgerygrouprespectively(P<0.05)・Con"elusion7、Intravitrealinjectionofhydroxycamptothecin(HCPT)andVerapamil(Ver)iseffectiveagainstproliferativevitreoretinopathy.Keywordshydroxycamptothecinverapamilvitreousbodyinjectionproliferativevitreoretinopathy增生性玻璃体视网膜病变(PVR)的发病机制是视网膜表而,玻璃体后而及视网膜下广泛纤维增殖膜收缩、牵拉[1〜8、3]o是原发性视网脱脱离常见的并发症及复位手术失败的主要原因,也是眼球灰部穿孔伤和各种原因引起的玻璃体积血并发牵引性视网膜脱离的病变基础[4,5]o玻璃体切割联合视网膜复位手术1=1前虽已有较高的成功率,可以去除玻璃体内增生物,但不能阻止细胞的继续增殖,术后复发常有发生[4]o本研究在动物实验及以往有关药物的临床应用研究的基础上[6-9],自200()年起,应川HCPT联合维拉帕米在安全剂量下,施行玻璃体切割术屮的玻璃体内注射,达到术后进一
3、lign=center>intreatmentofproliferativevitreoretinopathyRongAo,BiYanlong,LiWen,etal.DepartmentofOphthalmology,TongjiHospitalofTongjiUniversity,Shanghai200065・【Abstract]Objective
4、Toinvestigatetheinhibitoryeffectofintravitrealinjectionofhydroxycamptothecin(HCPT)andverapamil(Ver)onproliferativevitreoretinopathy.MethodsFifty-oneeyeswithretinaldetachmentcomplicatedwithproliferativevitreoretinopathyunderwentsurgeryandintravitrealinjec
5、tionofhydroxycamptothecin(HCPT)andverapami11(Ver)andfollow-upfor3〜5m()nths.Thecurativeeffectwascomparedwiththatofpurelysurgeryon37eyeswithretina]detachmentcomplicatedwithPVR.ResultsRetinalreattachmentwasfoundinmosteyesinbothgroupspostoperatively.Thecurer
6、atewas88.23%inthesurgeryplusinjectiongroupandwas70.2%inpurelysurgerygrouprespectively(P<0.05)・Theworseningrateofepiretinalmembraneandsubretinalmembranewasl3.72%inthesurgeryplusinjectiongroupand32.43%inthepurelysurgerygrouprespectively(P<0.05)・Con"elusion
7、Intravitrealinjectionofhydroxycamptothecin(HCPT)andVerapamil(Ver)iseffectiveagainstproliferativevitreoretinopathy.Keywordshydroxycamptothecinverapamilvitreousbodyinjectionproliferativevitreoretinopathy增生性玻璃体视网膜病变(PVR)的发病机制是视网膜表而,玻璃体后而及视网膜下广泛纤维增殖膜收缩、牵拉[1〜
8、3]o是原发性视网脱脱离常见的并发症及复位手术失败的主要原因,也是眼球灰部穿孔伤和各种原因引起的玻璃体积血并发牵引性视网膜脱离的病变基础[4,5]o玻璃体切割联合视网膜复位手术1=1前虽已有较高的成功率,可以去除玻璃体内增生物,但不能阻止细胞的继续增殖,术后复发常有发生[4]o本研究在动物实验及以往有关药物的临床应用研究的基础上[6-9],自200()年起,应川HCPT联合维拉帕米在安全剂量下,施行玻璃体切割术屮的玻璃体内注射,达到术后进一
此文档下载收益归作者所有